



AbbVie Files Form 8-K

NORTH CHICAGO, ILLINOIS, U.S.A., May 6, 2016 – AbbVie Inc. ("AbbVie") (NYSE / CHX / Euronext Paris / SIX: ABBV) today informs its stockholders that it has filed a Periodic Report on Form 8-K/A with the U.S. Securities and Exchange Commission ("SEC") amending the April 25, 2016 announcement regarding the Agreement and Plan of Merger (the "Merger Agreement") with Stemcentrx, Inc., a Delaware corporation ("Stemcentrx"), Sirius Sonoma Corporation, a Delaware corporation and wholly owned subsidiary of AbbVie, Sirius Sonoma LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie and, for certain purposes described in the Merger Agreement, Fertile Valley LLC, a Delaware limited liability company, pursuant to which Stemcentrx will be acquired by AbbVie.

AbbVie makes available free of charge on its website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed pursuant to Section 16 of the U.S. Securities Exchange Act of 1934 and amendments to those reports filed with or furnished to the SEC as soon as reasonably practicable after AbbVie electronically files these documents with, or furnishes them to, the SEC. These documents are posted on AbbVie's website at www.abbvieinvestor.com.

The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC. These materials may be obtained electronically by accessing the SEC's home page at <http://www.sec.gov>.

Copies of the above referenced information will also be made available, free of charge, upon written request to AbbVie Inc., Investors Relations, 1 North Waukegan Road, North Chicago, Illinois 60064, U.S.A.

Contact: AbbVie Inc., 1-847-938-8745